SBP-5147
SBP-5147 is an orally active ULK1/ULK2 inhibitor, with an IC50 of 2 nM against ULK1 and an IC50 of 53 nM against ULK2. SBP-5147 inhibits the phosphorylation of Beclin-1 and Vps34, reduces autophagy flux, downregulates the expression of ATG13 and ATG101, upregulates the expression of MHC-I, induces caspase-dependent apoptosis, and decreases the viability of non-small cell lung cancer cells. SBP-5147 is applicable to research related to non-small cell lung cancer[1].
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 1884222-37-0
- 화학식: C17H18F3N5
- 분자량:349.35
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
제품 설명
IC50 & Target
|
ULK2 53 nM (IC50) |
ULK1 2 nM (IC50) |
In Vitro
SBP-5147 (Compound 5) binds to intracellular ULK1 in HEK293T cells in NanoBRET assays, with an IC50 of 47 nM[1].
SBP-5147 (10 μM; 1 h) inhibits the phosphorylation levels of ULK1 downstream substrates Beclin-1 (Ser15) and Vps34 (Ser249) by approximately 80% in transfected HEK293T cells[1].
SBP-5147 (10 μM; 18 h) inhibits autophagic flux in A549 cells under nutrient starvation and reduces the population of cells with high autophagic flux[1].
SBP-5147 (72 h) reduces the viability of A549, HCC827, H1373 and H1975 cells, with IC50 values of 91, 49, 40 and 35 nM, respectively[1].
SBP-5147 (1 μM; 8-24 h) induces caspase-dependent apoptosis in A549 cells[1].
SBP-5147 (15-30 nM; 72 h) significantly upregulates the expression of total MHC-I protein in H1373, HCC827 and A549 cells[1].
SBP-5147 potently inhibits ULK1 kinase activity (IC50 = 2 nM) and ULK2 kinase activity (IC50 = 53 nM) in biochemical ADP-Glo assays[2].
SBP-5147 (48 h) induces the degradation of ATG13 in A549 non-small cell lung cancer (NSCLC) cells, with an IC50 of 4.5 μM[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HEK293T cells transfected with Myc-tagged WT ULK1 and Flag-tagged Beclin-1 or Vps34
-
Concentration:10 μM
-
Incubation Time:1 h
-
Result:Inhibited phosphorylation of Beclin-1 at Ser15 by roughly 80% relative to DMSO-treated cells.
Inhibited phosphorylation of Vps34 at Ser249 by roughly 80% relative to DMSO-treated cells.
-
Cell Line:A549 NSCLC cells expressing mCherry-GFP-LC3 reporter
-
Concentration:10 μM
-
Incubation Time:18 h
-
Result:Reduced the percentage of cells exhibiting high autophagic flux, shifting populations to intermediate and low flux relative to EBSS-only treated cells.
-
Cell Line:A549, H1975 NSCLC cells
-
Concentration:1 μM
-
Incubation Time:24 h (imaging); 8 h (Western blot)
-
Result:Induced caspase-dependent apoptotic cell death in A549 cells, with cell death abrogated by Emricasan and partially inhibited by zVAD-fmk.
Induced cleavage of PARP and caspase-3, blocked by apoptosis inhibitors.
-
Cell Line:H1373, HCC827, A549, H1975 NSCLC cell lines
-
Concentration:15 nM, 30 nM
-
Incubation Time:72 h
-
Result:Significantly increased total MHC-I protein expression at 30 nM in H1373, HCC827, and A549 cells.
Increased expression in H1373 and HCC827 cells also at 15 nM.
Had no significant effect on H1975 cells.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J (8-week-old female)[1]
-
Dosage:10 mg/kg
-
Administration:p.o.; single dose
-
Result:Caused progressive, significant decrease in ATG13 and ATG101 protein levels in liver and lung tissues.
Maintained significantly reduced ATG13 and ATG101 levels at 24 hours postdosing (plasma SBP-5147 almost completely eliminated) compared to vehicle-treated samples.
Confirmed statistically significant reductions in both proteins at 4, 8, and 24 hours postdosing relative to vehicle controls.
- Kinase activity and phosphorylation assays
- Western Blot
- RNA extraction experimental
- Detection of Apoptosis
- TUNEL staining for apoptotic DNA fragmentation
- Annexin V plus membrane-impermeant dye apoptosis staining
- Autophagy
- Apoptosis Solutions
- Protocol for Kinase activity and phosphorylation assays
- Lysosome and acidic-vesicle live-cell staining
- Macroautophagy Solutions
- Cell Viability Determination by MTT Colorimetric Assay
Parmacokinetics
| Species | Dose | Route | Tmax | Cmax | T1/2 |
|---|---|---|---|---|---|
| Mice[1] | 10 mg/kg | p.o. | 0.25 h | 664 nM | 2.5 h |
Chemical Information
-
CAS No. 1884222-37-0
-
분자량 349.35
-
화학식 C17H18F3N5
-
SMILES
FC(F)(F)C1=C(NC2CC2)N=C(NC3=CC(CCNC4)=C4C=C3)N=C1
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
References
[1]. Layng FIAL, et al. Synthesis and Characterization of ULK1/2 Kinase Inhibitors That Inhibit Autophagy and Upregulate Expression of Major Histocompatibility Complex I for the Treatment of Non-Small Cell Lung Cancer. ACS Chem Biol. 2026 Feb 12. [Content Brief]
[2]. Hagan PM, et al. ULK1/2 Inhibitors that Degrade ATG13 Effectively Target KRAS-Mutant Cancers. bioRxiv [Preprint]. 2025 Oct 15:2025.10.14.682402. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)